MENB ANTIBODIES IN INFANT BABOONS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。正在开发一种疫苗，以预防由B组脑膜炎奈瑟菌(MenB)引起的脑膜炎和败血症(血液感染)。6个月到2岁的婴儿和儿童患这种高致命性疾病的风险最大，目前美国和欧洲还没有批准疫苗。以前针对b型流感嗜血杆菌疫苗临床前开发的经验表明，婴儿狒狒是预测疫苗是否对人类婴儿有效的一个很好的指标。因此，我们的长期目标是在婴儿狒狒模型中测试实验性疫苗，以选择最好的抗原佐剂配方，供成人在婴儿中使用。人类临床研究表明，血液中存在一种特殊类型的抗体，称为血清杀菌抗体(SBA)，与预防细菌性脑膜炎有关。在我们对狒狒和人类婴儿的研究中，我们将使用SBA作为一个标记来预测疫苗的效果。有些人甚至在接种疫苗之前就已经感染了SBA，因为非致病性的奈瑟氏菌脑膜炎和一种类似的细菌可以在正常人类中定居。尽管被殖民的可能性随着年龄的增长而增加，但殖民率很低，而且是季节性的。需要接种疫苗才能在易感人群中诱发SBA。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A vaccine is being developed to prevent meningitis and sepsis (blood infection) caused by the bacterium Neisseria meningitidis group B (MenB). Infants and children aged 6 months to 2 years are at greatest risk of this highly lethal disease and currently there is no vaccine approved in the US or Europe. Previous experience with preclinical development of vaccines against the bacterium Haemophilus influenzae type b showed that infant baboons are a good predictor of whether a vaccine will be effective in human infants. Therefore our long term goal is to test experimental vaccines in the infant baboon model to select the best antigen-adjuvant formulation for use in human infants through adults. Human clinical studies have shown that the presence of a particular type of antibodies in blood termed serum bactericidal antibodies (SBA), correlates with protection from bacterial meningitis. In our studies of baboon and human infants we will use SBA as a marker to predict the efficacy of the vaccine. Some individuals have SBA even before they are immunized, because non-virulent varieties of Neisseria meningitis and one similar bacteria can colonize normal humans. Although the probability of colonization increases with age, colonization rates are low and seasonal. Vaccination is required to induce SBA in susceptible individuals.